甲状腺功能障碍与COVID-19免疫特征、疾病状态及结局的关系:191例患者分析
该研究纳入191例无已知甲状腺疾病的连续成人COVID-19患者,入院时检测甲状腺功能及抗体。13.1%存在甲状腺功能异常,低TSH与低fT3分别与SARS-CoV-2载量高和CRP升高独立相关,低fT3患者COVID-19相关结局更差。
要点
- 约15%的轻中度COVID-19患者出现甲状腺功能障碍。
- 低fT3与全身炎症相关,可能具有预后意义。
- SARS-CoV-2可能直接影响甲状腺功能。
核心结论
- 约15%的轻中度COVID-19患者存在甲状腺功能障碍,SARS-CoV-2可能直接影响甲状腺功能并可能加重既有的自身免疫性甲状腺疾病,低fT3与全身炎症相关且可能具有预后意义。
研究设计与样本
- 连续纳入2020年7月21日至8月21日因COVID-19入住Queen Mary Hospital的成人患者,均无已知甲状腺疾病,入院时检测TSH、游离甲状腺素、游离三碘甲状腺原氨酸及抗甲状腺抗体。
主要发现
- 191例患者中84.3%为轻型、12.6%为中型、3.1%为重型,13.1%存在甲状腺功能异常。
- 较低的SARS-CoV-2 PCR循环阈值和升高的C反应蛋白分别与低TSH(P = .030)和低fT3(P = .007)的发生独立相关。
- fT3随COVID-19严重程度增加呈下降趋势(P = .032),低fT3患者COVID-19相关不良结局更多。
关键数值与推荐
- 甲状腺功能异常定义为入院时甲状腺功能检测异常,见于13.1%的患者。
- 低TSH与较低SARS-CoV-2 PCR循环阈值独立相关(P = .030)。
- 低fT3与升高C反应蛋白独立相关(P = .007)。
- fT3随COVID-19严重程度增加呈下降趋势(P = .032)。
临床怎么用
- 对COVID-19患者应关注甲状腺功能,尤其低fT3可能提示全身炎症和不良预后。
- 低TSH需鉴别甲状腺炎所致亚临床甲状腺毒症与自身免疫性甲状腺病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related thyroiditis is increasingly recognized. The role of thyroid autoimmunity and SARS-CoV-2 viral load in SARS-CoV-2-related thyroid dysfunction is unclear. We evaluated the thyroid function of a cohort of coronavirus disease 2019 (COVID-19) patients, in relation to their clinical features, and biochemical, immunological, and inflammatory markers. METHODS: Consecutive adult patients, without known thyroid disorders, admitted to Queen Mary Hospital for COVID-19 from July 21 to August 21, 2020, were included. Serum levels of thyroid-stimulating hormone (TSH), free thyroxine, free triiodothyronine (fT3), and antithyroid antibodies were measured on admission. RESULTS: Among 191 patients with COVID-19 (mean age 53.5 ± 17.2 years; 51.8% male), 84.3% were mild, 12.6% were moderate, and 3.1% were severe. Abnormal thyroid function was seen in 13.1%. Ten patients had isolated low TSH, suggestive of subclinical thyrotoxicosis due to thyroiditis, although the contribution of autoimmunity was likely in 2 of them. Autoimmune thyroiditis probably also contributed to subclinical hypothyroidism in another patient. Ten patients had isolated low fT3, likely representing nonthyroidal illness syndrome. Lower SARS-Cov-2 polymerase chain reaction cycle threshold values and elevated C-reactive protein were independently associated with occurrence of low TSH (P = .030) and low fT3 (P = .007), respectively. A decreasing trend of fT3 with increasing COVID-19 severity (P = .032) was found. Patients with low fT3 had more adverse COVID-19-related outcomes. CONCLUSION: Around 15% of patients with mild to moderate COVID-19 had thyroid dysfunction. There may be a direct effect of SARS-CoV-2 on thyroid function, potentially leading to exacerbation of pre-existing autoimmune thyroid disease. Low fT3, associated with systemic inflammation, may have a prognostic significance.
引用
- Lui DTW, Lee CH, Chow WS, et al. Thyroid Dysfunction in Relation to Immune Profile, Disease Status, and Outcome in 191 Patients with COVID-19. J Clin Endocrinol Metab. 2021. PMID: 33141191. doi:10.1210/clinem/dgaa813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。